CLINICAL_TRIALS
trial_result
· 2011-05-19
Clinical Trial Update: TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial [Phase 2]
Summary
A Phase 2 trial (TMC125-C211) evaluated TMC125 in HIV-1 infected subjects who were in a sponsor-selected TMC125 trial; the study is completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infection | Phase 2 | Status: COMPLETED